Research progress of microRNAs as remodelers of lipid metabolic reprogramming in hepatocellular carcinoma

doi:10.16352/j.issn.1001-6325.2022.12.1930

Abstract

Abstract: Metabolic reprogramming is considered to be one of the top characteristics of tumor cells. Ample experimental studies have shown that microRNAs, which are a group of multifunctional non-coding RNAs, play an important role in the development of hepatocellular carcinoma (HCC) through lipid metabolic reprogramming. The current review briefly introduces the recent progress of specific microRNAs targeting at lipid metabolic reprogramming in HCC, which may provide a potential strategy for clinical targeting tumor therapy.

Key words: hepatocellular carcinoma, microRNAs, lipid metabolic reprogramming, tumorigenesis

CLC Number:

R735.7

WANG Yu-min, CHEN Ji-chao, WANG Hong-quan, WANG Jin-hua, TANG Bo. Research progress of microRNAs as remodelers of lipid metabolic reprogramming in hepatocellular carcinoma[J]. Basic & Clinical Medicine, 2022, 42(12): 1930-1934.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal11.magtechjournal.com/Jwk_jcyxylc/EN/10.16352/j.issn.1001-6325.2022.12.1930

http://journal11.magtechjournal.com/Jwk_jcyxylc/EN/Y2022/V42/I12/1930

References

[1]Nakagawa H, Hayata Y, Kawamura S, et al. Lipid metabolic reprogramming in hepatocellular carcinoma[J]. Cancers (Basel), 2018,10:447.doi: 10.3390/cancers10110447.
[2]Carracedo A, Cantley LC, Pandolfi PP. Cancer metabolism: fatty acid oxidation in the limelight[J]. Nat Rev Cancer, 2013,13:227-232.
[3]Budhu A, Roessler S, Zhao X, et al. Integrated metabolite and gene expression profiles identify lipid biomarkers associated with progression of hepatocellular carcinoma and patient outcomes[J]. Gastroenterology, 2013,144:1066-1075.
[4]Beloribi-Djefaflia S, Vasseur S, Guillaumond F. Lipid metabolic reprogramming in cancer cells[J]. Oncogenesis, 2016,5:e189.doi: 10.1038/oncsis.2015.49.
[5]Mosaoa R, Kasprzyk-Pawelec A, Fernandez HR, et al. The mitochondrial citrate carrier SLC25A1/CIC and the fundamental role of citrate in cancer, Inflammation and Beyond[J]. Biomolecules, 2021,11:141.doi: 10.3390/biom11020141.
[6]Zhao G, Dong L, Shi H, et al. MicroRNA-1207-5p inhibits hepatocellular carcinoma cell growth and invasion through the fatty acid synthase-mediated Akt/mTOR signalling pathway[J]. Oncol Rep, 2016,36:1709-1716.
[7]Wu H, Ng R, Chen X, et al. MicroRNA-21 is a potential link between non-alcoholic fatty liver disease and hepatocellular carcinoma via modulation of the HBP1-p53-Srebp1c pathway[J]. Gut, 2016,65:1850-1860.
[8]Zhang H, Feng Z, Huang R, et al. MicroRNA-449 suppresses proliferation of hepatoma cell lines through blockade lipid metabolic pathway related to SIRT1[J]. Int J Oncol, 2014,45:2143-2152.
[9]Li H, Chen Z, Zhang Y, et al. MiR-4310 regulates hepatocellular carcinoma growth and metastasis through lipid synthesis[J]. Cancer Lett, 2021,519:161-171.
[10]Lin YX, Wu XB, Zheng CW, et al. Mechanistic investigation on the regulation of FABP1 by the IL-6/miR-603 signaling in the pathogenesis of hepatocellular carcinoma[J]. Biomed Res Int, 2021:8579658.doi: 10.1155/2021/8579658.
[11]Bai PS, Xia N, Sun H, et al. Pleiotrophin, a target of miR-384, promotes proliferation, metastasis and lipo-genesis in HBV-related hepatocellular carcinoma[J]. J Cell Mol Med, 2017,21:3023-3043.
[12]Zare M, Panahi G, Koushki M, et al. Metformin reduces lipid accumulation in HepG2 cells via downregulation of miR-33b[J]. Arch Physiol Biochem, 2022,128:333-340.
[13]Yuan P, Mu J, Wang Z, et al. Down-regulation of SLC25A20 promotes hepatocellular carcinoma growth and metastasis through suppression of fatty-acid oxidation[J]. Cell Death Dis, 2021,12:361.doi:10.1038/s41419-021-03648-1.
[14]Liu Y, Lu LL, Wen D, et al. MiR-612 regulates invadopodia of hepatocellular carcinoma by HADHA-mediated lipid reprogramming[J]. J Hematol Oncol, 2020,13:12.doi: 10.1186/s13045-019-0841-3.
[15]Vanni S. Intracellular lipid droplets: from structure to function[J]. Lipid Insights, 2017,10:1178635317745518.doi: 10.1177/1178635317745518.
[16]Koizume S, Miyagi Y. Lipid droplets: akey cellular organelle associated with cancer cell survival under normoxia and hypoxia[J]. Int J Mol Sci, 2016,17.doi: 10.3390/ijms17091430.
[17]Baenke F, Peck B, Miess H, et al. Hooked on fat: the role of lipid synthesis in cancer metabolism and tumour development[J]. Dis Model Mech, 2013,6:1353-1363.
[18]Hsu SH, Wang B, Kota J, et al. Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver[J]. J Clin Invest, 2012,122:2871-2883.
[19]Guo XY, He CX, Wang YQ, et al. Circular RNA profiling and bioinformatic modeling identify its regulatory role in hepatic steatosis[J]. Biomed Res Int, 2017,2017:5936171.doi: 10.1155/2017/5936171.
[20]Zhang Q, Ma XF, Dong MZ, et al. MiR-30b-5p regulates the lipid metabolism by targeting PPARGC1A in Huh-7 cell line[J]. Lipids Health Dis, 2020,19:76.doi: 10.1186/s12944-020-01261-3.
[21]Yan S, Yang XF, Liu HL, et al. Long-chain acyl-CoA synthetase in fatty acid metabolism involved in liver and other diseases: an update[J]. World J Gastroenterol, 2015,21:3492-3498.
[22]Cui M, Wang Y, Sun B, et al. MiR-205 modulates abnormal lipid metabolism of hepatoma cells via targeting acyl-CoA synthetase long-chain family member 1 (ACSL1) mRNA[J]. Biochem Biophys Res Commun, 2014,444:270-275.
[23]Cui M, Xiao Z, Sun B, et al. Involvement of cholesterol in hepatitis B virus X protein-induced abnormal lipid metabolism of hepatoma cells via up-regulating miR-205-targeted ACSL4[J]. Biochem Biophys Res Commun, 2014,445:651-655.
[24]Guo J, Fang W, Sun L, et al. Ultraconserved element uc.372 drives hepatic lipid accumulation by suppressing miR-195/miR4668 maturation[J]. Nat Commun, 2018,9:612.doi: 10.1038/s41467-018-03072-8.